Abstract
Twenty-two specific-pathogen-free beagles were vaccinated with recombinant OspA (ospA gene derived from Borrelia burgdorferi B31) alone or with adjuvant (QuilA, Montanide ISA25, or aluminum hydroxide) at 6 weeks of age. Thirteen dogs were used as nonvaccinated controls with or without adjuvant. Three dogs were kept as contact controls and received neither vaccine nor challenge. Six weeks or 6 months after the first vaccination, the vaccinated (20 of 22) and nonvaccinated dogs (13) were challenged by exposure to adult ticks (Ixodes scapularis) naturally that were infected with B. burgdorferi (tick infection rate, > or = 60%) and that were collected from Westchester County, N.Y. Protection from infection was evaluated by culture for B. burgdorferi from skin biopsies taken near the sites of tick bites. Skin biopsies were taken at monthly intervals for 3 months. B. burgdorferi was not isolated from any of the vaccinated dogs. In contrast, 12 of 13 control dogs challenged by exposure to the ticks were culture positive. The histopathology of the joint capsules 3 months after the challenge was used to evaluate protection from arthritis. Eight of 13 control dogs showed synovitis in single or multiple joints, while only 1 of the 22 vaccinated dogs had a single focus of mild inflammation in a single joint. At the time of the challenge, the vaccinated dogs had antibody to B. burgdorferi, which was demonstrable by kinetic enzyme-linked immunosorbent assay, Western blotting (immunoblotting), and a serum growth inhibition assay. The vaccinal antibody declined gradually after the challenge, especially in dogs vaccinated with OspA without adjuvants. Antibodies in the challenge control dogs were only detectable by 4 to 6 weeks after the challenge and remained at high levels until the termination of the study. Contact control dogs showed no antibody responses or histopathologic lesions and were culture negative. By Western blot analysis, antibodies to OspA first appeared in the sera of vaccinated dogs 3 weeks after the first vaccination. The absence of additional bands after the challenge suggests that infection in vaccinated dogs was blocked. Results from this study show that vaccination with recombinant OspA protected dogs against infection and disease after an experimental challenge with B. burgdorferi by exposure to ticks.
Full Text
The Full Text of this article is available as a PDF (511.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Appel M. J., Allan S., Jacobson R. H., Lauderdale T. L., Chang Y. F., Shin S. J., Thomford J. W., Todhunter R. J., Summers B. A. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993 Mar;167(3):651–664. doi: 10.1093/infdis/167.3.651. [DOI] [PubMed] [Google Scholar]
- Baranton G., Postic D., Saint Girons I., Boerlin P., Piffaretti J. C., Assous M., Grimont P. A. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol. 1992 Jul;42(3):378–383. doi: 10.1099/00207713-42-3-378. [DOI] [PubMed] [Google Scholar]
- Burgess E. C. Borrelia burgdorferi infection in Wisconsin horses and cows. Ann N Y Acad Sci. 1988;539:235–243. doi: 10.1111/j.1749-6632.1988.tb31857.x. [DOI] [PubMed] [Google Scholar]
- Chang Y. F., Lauderdale T. L., Lee W. Y., Shin S. J., Jacobson R. H., Appel M. J., Lein D. H. Expression and secretion of outer surface protein (OSP-A) of Borrelia burgdorferi from Escherichia coli. FEMS Microbiol Lett. 1993 May 15;109(2-3):297–301. doi: 10.1016/0378-1097(93)90036-2. [DOI] [PubMed] [Google Scholar]
- Chu H. J., Chavez L. G., Jr, Blumer B. M., Sebring R. W., Wasmoen T. L., Acree W. M. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc. 1992 Aug 1;201(3):403–411. [PubMed] [Google Scholar]
- Ciesielski C. A., Markowitz L. E., Horsley R., Hightower A. W., Russell H., Broome C. V. The geographic distribution of Lyme disease in the United States. Ann N Y Acad Sci. 1988;539:283–288. doi: 10.1111/j.1749-6632.1988.tb31862.x. [DOI] [PubMed] [Google Scholar]
- Dykhuizen D. E., Polin D. S., Dunn J. J., Wilske B., Preac-Mursic V., Dattwyler R. J., Luft B. J. Borrelia burgdorferi is clonal: implications for taxonomy and vaccine development. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10163–10167. doi: 10.1073/pnas.90.21.10163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Erdile L. F., Brandt M. A., Warakomski D. J., Westrack G. J., Sadziene A., Barbour A. G., Mays J. P. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun. 1993 Jan;61(1):81–90. doi: 10.1128/iai.61.1.81-90.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fikrig E., Barthold S. W., Flavell R. A. OspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection. Infect Immun. 1993 Jun;61(6):2553–2557. doi: 10.1128/iai.61.6.2553-2557.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fikrig E., Barthold S. W., Kantor F. S., Flavell R. A. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun. 1992 Mar;60(3):773–777. doi: 10.1128/iai.60.3.773-777.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fikrig E., Barthold S. W., Kantor F. S., Flavell R. A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science. 1990 Oct 26;250(4980):553–556. doi: 10.1126/science.2237407. [DOI] [PubMed] [Google Scholar]
- Fikrig E., Barthold S. W., Kantor F. S., Flavell R. A. Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. J Infect Dis. 1991 Dec;164(6):1224–1227. doi: 10.1093/infdis/164.6.1224. [DOI] [PubMed] [Google Scholar]
- Fikrig E., Barthold S. W., Marcantonio N., Deponte K., Kantor F. S., Flavell R. A. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun. 1992 Feb;60(2):657–661. doi: 10.1128/iai.60.2.657-661.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fikrig E., Telford S. R., 3rd, Barthold S. W., Kantor F. S., Spielman A., Flavell R. A. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5418–5421. doi: 10.1073/pnas.89.12.5418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gern L., Rais O., Capiau C., Hauser P., Lobet Y., Simoen E., Voet P., Pêtre J. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites. Immunol Lett. 1994 Mar;39(3):249–258. doi: 10.1016/0165-2478(94)90166-x. [DOI] [PubMed] [Google Scholar]
- Grauer G. F., Burgess E. C., Cooley A. J., Hagee J. H. Renal lesions associated with Borrelia burgdorferi infection in a dog. J Am Vet Med Assoc. 1988 Jul 15;193(2):237–239. [PubMed] [Google Scholar]
- Kazmierczak J. J., Sorhage F. E. Current understanding of Borrelia burgdorferi infection, with emphasis on its prevention in dogs. J Am Vet Med Assoc. 1993 Dec 1;203(11):1524–1528. [PubMed] [Google Scholar]
- Keller D., Koster F. T., Marks D. H., Hosbach P., Erdile L. F., Mays J. P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA. 1994 Jun 8;271(22):1764–1768. [PubMed] [Google Scholar]
- Kornblatt A. N., Urband P. H., Steere A. C. Arthritis caused by Borrelia burgdorferi in dogs. J Am Vet Med Assoc. 1985 May 1;186(9):960–964. [PubMed] [Google Scholar]
- Levy S. A., Lissman B. A., Ficke C. M. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas. J Am Vet Med Assoc. 1993 Jun 1;202(11):1834–1838. [PubMed] [Google Scholar]
- Levy S. A., Magnarelli L. A. Relationship between development of antibodies to Borrelia burgdorferi in dogs and the subsequent development of limb/joint borreliosis. J Am Vet Med Assoc. 1992 Feb 1;200(3):344–347. [PubMed] [Google Scholar]
- Lim L. C., England D. M., DuChateau B. K., Glowacki N. J., Creson J. R., Lovrich S. D., Callister S. M., Jobe D. A., Schell R. F. Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immun. 1994 Jul;62(7):2825–2833. doi: 10.1128/iai.62.7.2825-2833.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lissman B. A., Bosler E. M., Camay H., Ormiston B. G., Benach J. L. Spirochete-associated arthritis (Lyme disease) in a dog. J Am Vet Med Assoc. 1984 Jul 15;185(2):219–220. [PubMed] [Google Scholar]
- Lovrich S. D., Callister S. M., Lim L. C., DuChateau B. K., Schell R. F. Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe. J Infect Dis. 1994 Jul;170(1):115–121. doi: 10.1093/infdis/170.1.115. [DOI] [PubMed] [Google Scholar]
- Ma J., Bulger P. A., Davis D. R., Perilli-Palmer B., Bedore D. A., Kensil C. R., Young E. M., Hung C. H., Seals J. R., Pavia C. S. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi. Vaccine. 1994 Aug;12(10):925–932. doi: 10.1016/0264-410x(94)90036-1. [DOI] [PubMed] [Google Scholar]
- Magnarelli L. A., Anderson J. F., Levine H. R., Levy S. A. Tick parasitism and antibodies to Borrelia burgdorferi in cats. J Am Vet Med Assoc. 1990 Jul 1;197(1):63–66. [PubMed] [Google Scholar]
- Nguyen T. P., Lam T. T., Barthold S. W., Telford S. R., 3rd, Flavell R. A., Fikrig E. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infect Immun. 1994 May;62(5):2079–2084. doi: 10.1128/iai.62.5.2079-2084.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parker J. L., White K. K. Lyme borreliosis in cattle and horses: a review of the literature. Cornell Vet. 1992 Jul;82(3):253–274. [PubMed] [Google Scholar]
- Preac-Mursic V., Wilske B., Patsouris E., Jauris S., Will G., Soutschek E., Rainhardt S., Lehnert G., Klockmann U., Mehraein P. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection. 1992 Nov-Dec;20(6):342–349. doi: 10.1007/BF01710681. [DOI] [PubMed] [Google Scholar]
- Probert W. S., LeFebvre R. B. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun. 1994 May;62(5):1920–1926. doi: 10.1128/iai.62.5.1920-1926.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Péter O., Bretz A. G. Polymorphism of outer surface proteins of Borrelia burgdorferi as a tool for classification. Zentralbl Bakteriol. 1992 Jun;277(1):28–33. doi: 10.1016/s0934-8840(11)80867-4. [DOI] [PubMed] [Google Scholar]
- Sadziene A., Thompson P. A., Barbour A. G. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis. 1993 Jan;167(1):165–172. doi: 10.1093/infdis/167.1.165. [DOI] [PubMed] [Google Scholar]
- Schaible U. E., Wallich R., Kramer M. D., Gern L., Anderson J. F., Museteanu C., Simon M. M. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Vaccine. 1993;11(10):1049–1054. doi: 10.1016/0264-410x(93)90132-h. [DOI] [PubMed] [Google Scholar]
- Shin S. J., Chang Y. F., Jacobson R. H., Shaw E., Lauderdale T. L., Appel M. J., Lein D. H. Cross-reactivity between B. burgdorferi and other spirochetes affects specificity of serotests for detection of antibodies to the Lyme disease agent in dogs. Vet Microbiol. 1993 Jul;36(1-2):161–174. doi: 10.1016/0378-1135(93)90137-V. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simon M. M., Schaible U. E., Kramer M. D., Eckerskorn C., Museteanu C., Müller-Hermelink H. K., Wallich R. Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis. 1991 Jul;164(1):123–132. doi: 10.1093/infdis/164.1.123. [DOI] [PubMed] [Google Scholar]
- Simon M. M., Schaible U. E., Wallich R., Kramer M. D. A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease. Immunol Today. 1991 Jan;12(1):11–16. doi: 10.1016/0167-5699(91)90106-4. [DOI] [PubMed] [Google Scholar]
- Steere A. C. Lyme disease. N Engl J Med. 1989 Aug 31;321(9):586–596. doi: 10.1056/NEJM198908313210906. [DOI] [PubMed] [Google Scholar]
- Steere A. C., Malawista S. E., Snydman D. R., Shope R. E., Andiman W. A., Ross M. R., Steele F. M. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum. 1977 Jan-Feb;20(1):7–17. doi: 10.1002/art.1780200102. [DOI] [PubMed] [Google Scholar]
- Stover C. K., Bansal G. P., Hanson M. S., Burlein J. E., Palaszynski S. R., Young J. F., Koenig S., Young D. B., Sadziene A., Barbour A. G. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med. 1993 Jul 1;178(1):197–209. doi: 10.1084/jem.178.1.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Telford S. R., 3rd, Fikrig E., Barthold S. W., Brunet L. R., Spielman A., Flavell R. A. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J Exp Med. 1993 Aug 1;178(2):755–758. doi: 10.1084/jem.178.2.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilske B., Preac-Mursic V., Göbel U. B., Graf B., Jauris S., Soutschek E., Schwab E., Zumstein G. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J Clin Microbiol. 1993 Feb;31(2):340–350. doi: 10.1128/jcm.31.2.340-350.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]